Kevin A. Pokornowski

Author

Bristol-Myers Squibb (United States)

Also Known As

K Pokornowski, K. Pokornowski, K.A. Pokornowski, Kevin A. Pokornowski, Kevin Pokornowski

Publications

2.5K

Citations

H-Index

Concepts

All Affiliations

Bristol-Myers Squibb (United States)Bristol-Myers Squibb (Germany)

About

Kevin A. Pokornowski is an author at Bristol-Myers Squibb (United States) specializing in medicine, virology, and viral hepatitis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	1.3K
2	Natural Sciences	2	2	47
3	Biochemistry	2	2	47
4	Biomolecular Engineering	2	2	99
5	Health Sciences	1	1	537

Kevin A. Pokornowski

Publications

2.5K

Citations

H-Index

Page 1

	Year	Citations
Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy # Daniel J. Tenney, Ronald E. Rose, Carl J. Baldick, Hepatology	2009	810
Clinical Emergence of Entecavir-Resistant Hepatitis B Virus Requires Additional Substitutions in Virus Already Resistant to Lamivudine Daniel J. Tenney, Steven M. LeVine, R.E. Rose, Antimicrobial Agents and Chemotherapy VaccinationClinical EmergenceHealth SciencesViral HepatitisAntiviral Drug Development	2004	537
Entecavir resistance is rare in nucleoside naïve patients with hepatitis B Richard J. Colonno, Ronald E. Rose, Carl J. Baldick, Hepatology Diagnostic VirologyHbv ReplicationHepatologyViral HepatitisImmunodeficiencies	2006	347
Two-Year Assessment of Entecavir Resistance in Lamivudine-Refractory Hepatitis B Virus Patients Reveals Different Clinical Outcomes Depending on the Resistance Substitutions Present Daniel J. Tenney, Ronald E. Rose, Carl J. Baldick, Antimicrobial Agents and Chemotherapy	2006	239
[781] FOUR YEAR ASSESSMENT OF ETV RESISTANCE IN NUCLEOSIDE-NAIVE AND LAMIVUDINE REFRACTORY PATIENTS Richard Colonno, R.E. Rose, Kevin A. Pokornowski, Journal of Hepatology MedicineResistance Mutation (Virology)Drug Resistance	2007	115
Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance Carl J. Baldick, Daniel J. Tenney, Charles E. Mazzucco, Hepatology	2008	96
A Novel Small Molecule Inhibitor of Hepatitis C Virus Entry Carl J. Baldick, Michael Wichroski, Annapurna Pendri, PLoS Pathogens Small Molecule InhibitorsImmunologyAntiviral DrugViral HepatitisAntiviral Drug Development	2010	82
Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response Carl J. Baldick, Betsy J. Eggers, Jie Fang, Journal of Hepatology Viral PersistenceViral HepatitisPathogenesisHepatitis BHepatitis	2008	68
20 ENTECAVIR MAINTAINS A HIGH GENETIC BARRIER TO HBV RESISTANCE THROUGH 6 YEARS IN NAIVE PATIENTS Daniel J. Tenney, Kevin A. Pokornowski, R.E. Rose, Journal of Hepatology NeurovirologyViral HepatitisImmunologyAntiviral TherapyResistance Mutation (Virology)	2009	65
The N-terminal portion of domain E of retinoic acid receptors alpha and beta is essential for the recognition of retinoic acid and various analogs. Jerzy Ostrowski, Laura Hammer, Thor Roalsvig, Proceedings of the National Academy of Sciences Retinoic AcidMolecular BiologyMolecular PharmacologyTranscriptional RegulationDomain Exchange	1995	30

Page 1